Chordia Looks To Forge Own Path In Oncology

Japan Venture Progresses Ex-Takeda Assets

Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.

Leukemia
Leukemia Is Among The Target Indications For Japan's Chordia • Source: Shutterstock

Chordia Therapeutics Inc is among a number of new Japanese bioventures born out of former research activities at Takeda Pharmaceutical Co. Ltd., but is now looking to blaze its own trail as it progresses a number of novel oncology assets.

The Fujisawa-based operation was formed in November 2017 around a portfolio of selected assets that originally came out of the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia